Neurological symptoms and disability in HTLV-1 associated myelopathy;Manifestaciones neurológicas y discapacidad en pacientes que padecen mielopatía asociada al HTLV-1

Neurologia

Volumn 23, Issue 2, 2008, Pages 78-84

  Carod Artal, Francisco Javier ^a   Mourao Mesquita H ^a   Da Silveira Ribeiro, L ^a   Carod Artal, F J ^b  

^a SARAH NETWORK OF REHABILITATION HOSPITALS   (Brazil)

^b NONE

Author keywords

Disability; HTLV I associated myelopathy; Human T cell lymphotropic virus type 1 (HTLV I); Tropical spastic paraparesis

Indexed keywords

ADULT; ARTICLE; ATAXIA; BABINSKI REFLEX; BARTHEL INDEX; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ELECTROMYOGRAM; ENZYME LINKED IMMUNOSORBENT ASSAY; EVOKED RESPONSE; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; HYPERREFLEXIA; MAJOR CLINICAL STUDY; MALE; MUSCLE ATROPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIPHERAL NEUROPATHY; SPASTIC PARAPLEGIA; SPINAL CORD ATROPHY; VIRUS INFECTION; WESTERN BLOTTING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ATAXIA; CEREBRAL CORTEX; CHILD; DISABILITY EVALUATION; FEMALE; HTLV-I INFECTIONS; HUMANS; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION; PARAPARESIS, TROPICAL SPASTIC; QUESTIONNAIRES; RISK FACTORS; SPINAL CORD; SURAL NERVE;

EID: 42049086292     PISSN: 02134853     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Gessain A, Barin F, Vernant JC, Gout O, Maurs L, Calender A, et al. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet 1985;ii:407-10.
2. Osame M, Usuku K, Izumo S, Ijichi N, Amitani H, Igata A, et al. HTLV-I associated myelopathy, a new clinical entity. Lancet 1986;ii:1031-2.
3. Maloney EM, Cleghorn FR, Morgan OS, Rodgers-Johnson P, Cranston B, Jack N, et al. Incidence of HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Jamaica and Trinidad. J Acquir Immune Defic Syndr Hum Retrovirol 1998;17:167-70.
4. Proietti FA, Carneiro-Proietti AB, Catalan-Soares BC, Murphy EL. Global epidemiology of HTLV-I infection and associated diseases. Oncogene 2005;24:6058-68.
5. Diop S, Calattini S, Abah-Dakou J, Thiam D, Diakhate L, Gessain A. Seroprevalence and molecular epidemiology of human T-cell leukemia virus type 1 (HTLV-1) and HTLV-2 in blood donors from Dakar, Senegal. J Clin Microbiol 2006;44:1550-4.
6. Morofuji-Hirata M, Kajiyama W, Nakashima K, Noguchi A, Hayashi J, Kashiwaqi S. Prevalence of antibody to human T-cell lymphotropic virus type I in Okinawa, Japan, after an interval of 9 years. Am J Epidemiol 1993;137:43-8.
7. Carod Artal FJ. Enfermedad de Chagas e ictus. Neurologia 2006;21:135-49.
8. Dougan S, Smith A, Tosswill JC, Davison K, Zuckerman M, Taylor GP. New diagnoses of HTLV infection in England and Wales: 2002-2004. Euro Surveill 2005;10:232-5.
9. Toro C, Rodes B, Aguilera A, Caballero E, Benito R, Bassani S, et al. Grupo Español para el Estudio del VIH-2 y del HTLV-I/II. Infecciones por VIH-2 y HTLV-I/II en España. Enferm Infecc Microbiol Clin 2004;22:177-82.
10. Orland JR, Engstrom J, Fridey J, Sacher RA, Smith JW, Nass C et al, HTLV Outcomes Study. Prevalence and clinical features of HTLV neurologic disease in the HTLV Outcomes Study. Neurology 2003;61:1588-94.
11. Dehee A, Cesaire R, Desire N, Lezin A, Bourdonne O, Bera O, et al. Quantitation of HTLV-I proviral load by a TaqMan real-time PCR assay. J Virol Methods 2002;102:37-51.
12. Osame M. Review of WHO Kagoshima meeting and diagnostic guidelines for HAM/TSP. En: Blattner W, editor. Human retrovirology HTLV. New York: Raven Press, 1990; p. 191-7.
13. Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 1987;67:206-7.
14. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-52.
15. Mahoney FI, Barthel DW. Functional evaluation: the Barthel index. Md State Med J 1965;14:61-5.
16. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361-70.
17. Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 Health survey. Manual and interpretation guide. Boston: Nimrod Press, 1993.
18. Grindstaff P, Gruener G. The peripheral nervous system complications of HTLV-1 myelopathy (HAM/TSP) syndromes. Semin Neurol 2005;25:315-27.
19. Carod-Artal FJ, Melo M, Alves R, Brenner C, del Negro MC. Formas subagudas de infección por el virus HTLV-I potencialmente tratables. Rev Neurol 2000;31:32-5.
20. Carod-Artal FJ, del Negro MC, Vargas AP, Rizzo I. Sindrome cerebelar y neuropatia periférica como manifestación de la infección por el virus linfotrópico humano de células T, HTLV-I. Rev Neurol 1999;29:932-5.
21. Leite AC, Silva MT, Alamy AH, Afonso CR, Lima MA, Andrada-Serpa MJ, et al. Peripheral neuropathy in HTLV-I infected individuals without tropical spastic paraparesis/HTLV-I-associated myelopathy. J Neurol 2004;25:877-81.
22. Carod FJ, Magnani BM, Kalil RK, Campos da Paz A. Neurological manifestations and MRI findings in 29 brazilian patients with tropical spastic paraparesis/HTLV-I associated myelopathy (TSP/HAM) in Brazil. Neurology 2000;54(Suppl. 3):173.
23. Carod Artal F. Esclerosis múltiple o infección por HTLV-I? Neurologia 2000;15:371.
24. Nakagawa M, Izumo S, Ijichi S, Kubota H, Arimura K, Kawabata M, et al. HTLV-I-associated myelopathy: analysis of 213 patients based on clinical features and laboratory findings. J Neurovirol 1995;1:50-61.
25. Olindo S, Cabre P, Lezin A, Merle H, Saint-Vil M, Signate A, et al. Natural history of human T-lymphotropic virus 1-associated myelopathy: a 14 year follow-up study. Arch Neurol 2006;63:1560-6.
26. Franzoi AC, Araujo AQ. Disability profile of patients with HTLV-I-associated myelopathy/tropica I spastic paraparesis using the Functional independence measure (FIM). Spinal Cord 2005;43:236-40.
27. Kuroda Y, Fujiyama F, Nagumo F. Analysis of factors or relevance to rapid clinical progression of HTLV-I-associated myelopathy. J Neurol Sci 1991;105:61-6.
28. Gout O, Baulac M, Gessain A, Semah F, Saal F, Peries J, et al. Rapid development of myelopathy after HTLV-I infection acquired by transfusion during cardiac transplantation. N Engl J Med 1990;322:383-8.
29. Zarranz Imirizaldu JJ, Gomez Esteban JC, Rouco Axpe I, Pérez Concha T, Velasco Juanes F, Allue Susaeta I, et al. Post-transplantation HTLV-1 myelopathy in three recipients from a single donor. J Neurol Neurosurg Psychiatry 2003;74:1080-4.
30. Olindo S, Lezin A, Cabre P, Merle H, Saint-Vil M, Edimonana Kaptue M, et al. HTLV-1 proviral load in peripheral blood mononuclear cells quantified in 100 HAM/TSP patients: a marker of disease progression. J Neurol Sci 2005;237:53-9.
31. Matsuzaki T, Nakagawa M, Nagai M, Usuku K, Higuchi I, Arimura K, et al. HTLV-I proviral load correlates with progression of motor disability in HAM/TSP: analysis of 239 HAM/TSP patients including 64 patients followed up for 10 years. J Neurovirol 2001;7:228-34
32. Cottrell DA, Kremenchutzky M, Rice GPA, Koopman WJ, Hader W, Baskerville J, et al. The natural history of multiple sclerosis: a geographically based study, 5: the clinical features and natural history of primary progressive multiple sclerosis. Brain 1999;122:625-39.
33. Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000;343:1430-8.
34. Beilke MA, Japa S, Moeller-Hadi C, Martin-Schild S. Tropical spastic paraparesis/human T leukemia virus type 1-associated myelopathy in HIV type 1-coinfected patients. Clin Infect Dis 2005;41:e57-63.